New enzyme combo aims to boost leukemia treatment in High-Risk adults
NCT ID NCT06918431
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new form of the drug asparaginase (made from a different bacterium) can be safely combined with standard chemotherapy for high-risk adults aged 18–54 with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma. The treatment aims to kill cancer cells by breaking down an amino acid they need to grow. Researchers will monitor side effects and how well the cancer responds.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA, PHILADELPHIA CHROMOSOME NEGATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
-
City of Hope at Irvine Lennar
NOT_YET_RECRUITINGIrvine, California, 92618, United States
-
City of Hope at Phoenix
RECRUITINGPhoenix, Arizona, 85338, United States
-
Cleveland Clinic Foundation
NOT_YET_RECRUITINGCleveland, Ohio, 44195, United States
-
Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITINGNew York, New York, 10065, United States
-
UC San Diego Moores Cancer Center
NOT_YET_RECRUITINGLa Jolla, California, 92093, United States
-
UCLA / Jonsson Comprehensive Cancer Center
NOT_YET_RECRUITINGLos Angeles, California, 90095, United States
-
University of Chicago Comprehensive Cancer Center
NOT_YET_RECRUITINGChicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chemo-Antibody combo beat a tough leukemia?
- Can a smart drug missile tame Hard-to-Treat leukemia?
- Personalized chemo dosing may boost survival in kids with High-Risk leukemia
- Engineered immune cells take aim at Hard-to-Treat T-Cell cancers
- Engineered immune cells take aim at stubborn blood cancers
- Double-Barreled immune attack aims to wipe out T-ALL